HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain
March 21st 2023Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.
Integrating New Standards for Metastatic HER2+ Breast Cancer
March 20th 2023The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.
Coleman Illuminates Opportunities in Gynecologic Malignancies
March 17th 2023Robert L. Coleman, MD, FACOG, FACS, the 2020 Giants of Cancer Care® award winner in gynecologic malignancies, notes that despite the great progress in the past decade, more work is needed to personalize and refine approaches to care.
Diagnostic Cancer Trends Showcase Urgent Need to Increase HPV Vaccination
March 16th 2023As the great baseball catcher and philosopher Yogi Berra noted, “When you come to a fork in the road, take it.” And in my opinion, we surely are at that juncture with human papillomavirus vaccination.